GBS, Inc. (GBS)
|Net Income (ttm)||n/a|
|Trading Day||March 5|
|Day's Range||5.80 - 6.51|
|52-Week Range||5.71 - 14.24|
GBS Inc. Enters Sponsored Research Agreement with Johns Hopkins Bloomberg School of Public Health To Accelerate Development of Saliva-Based Diagnostic Tests
NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company that develops non-invasive, real-time point of care (POC) diagnostic tests for patients and their pr...
NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- GBS Inc. (the “Company”) (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and t...
GBS and Inhibikase Therapeutics priced late Tuesday.
Will Trade on the Nasdaq Global Market Under Ticker “GBS” Will Trade on the Nasdaq Global Market Under Ticker “GBS”
Will Trade on the Nasdaq Global Market Under Ticker “GBS”
GBS, which is developing saliva-based tests for SARS-CoV-2 and diabetes management in China, lowered the proposed deal size for its upcoming IPO on Tuesday. The New York, NY-based company now ...
GBS operates as a biosensor diagnostic technology company. Its principal product is Saliva Glucose Biosensor, a saliva glucose monitoring system for diabetes management. The company also focuses on developing other diagnostic tests in the areas of biochemistry, tumor markers, immunology, hormones, and other biomarkers. GBS Inc. was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was founded in 2016 and is headquartered in New York, New York. GBS Inc. is a... [Read more...]
|IPO Date |
Dec 23, 2020
|Stock Exchange |
|Ticker Symbol |
In 2020, GBS, Inc.'s revenue was $188,841, an increase of 100,347.34% compared to the previous year's $188. Losses were -$3.13 million, -57.27% less than in 2019.